Zevra Therapeutics Inc (ZVRA) Implied Volatility Current

Tracking ZVRA implied volatility helps you identify when options premiums on Zevra Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Zevra Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when ZVRA IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Zevra Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ZVRA, tracking metrics like ZVRA IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ZVRA signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).

The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ZVRA implied volatility sits today versus where it has been. Our scanner ranks Zevra Therapeutics Inc implied volatility against its historical range, surfaces extremes in ZVRA IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Zevra Therapeutics Inc IV is rich or cheap — measure it, then act on it.